Dr Reddy's Labs lines up Rs 1,500 crore capex with focus on biosimilars, injectables

Elaborating on the overall strategies, Dr Reddy's Laboratories CEO Erez Israeli said the company's R&D is focusing on creating "as much as possible on differentiated products, on biosimilars, on products that have bigger potential."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SN2myQg
via IFTTT